



## RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS

*Milan, 22<sup>nd</sup> February 2021* – As a follow-up to the press release issued earlier today, Recordati S.p.A. informs that, in execution of the resolution adopted by the Shareholders' meeting held on 29<sup>th</sup> April 2020, it has granted a mandate to J.P. Morgan AG (the "Intermediary") to execute – in full independency ("riskless principal") - a share buy-back program under art. 5 of (EU) Regulation no. 596/2014 (the "Program"), on behalf of the Company.

The Program involves the acquisition of Recordati ordinary shares for the servicing of current and future stock option plans in favour of the Recordati Group's management.

The details of the Programme are the following:

- **Maximum number of shares:** the acquisition could involve a maximum of up to 1,500,000 ordinary nominal value Euro 0.125 Recordati shares and hence within the legal limit (1/5 of the company's entire share capital as established by art. 2357, paragraph 3 of the Italian Civil Code), including any shares owned by the Company.  
As of 19<sup>th</sup> February 2021, the Company had no. 2,813,302 shares in Treasury stock which amounts to 1.3452% of the share capital.
- **Minimum and maximum consideration payable and maximum cash outlay:** the minimum purchase price for the ordinary shares shall not be lower than the share's nominal value (Euro 0.125), while the maximum purchase price shall not exceed the average official Stock Exchange price recorded over the 5 trading days prior to the transaction, plus 5%, within the maximum cash outlay of Eur 75 million (seventy five million).
- **Duration:** until the expiry of the authorization granted by the Shareholders' meeting held on 29<sup>th</sup> April 2020 and consequently until the approval by the Shareholders' meeting of the 2020 financial statements (i.e. until 20<sup>th</sup> April 2021).
- **Buyback procedures:** in compliance with art. 132 of the Legislative Decree 58/1998 and art. 144-bis, paragraph 1, letter b) of the Issuers Regulation, as well as in compliance with EU Regulation 596/2014 and its relative implementing provisions (also with reference to the purchase price and the daily volume allowed) where applicable and in line with the authorization of the Shareholders' Meeting.

Any subsequent changes to the programme will be promptly disclosed to the public according to the conditions and deadlines set forth by the applicable law.

The operations carried out will be disclosed to the market according to the deadlines and conditions set forth by the regulatory provisions currently in force.

**Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, proprietary and under license, in a number of therapeutic areas including a specialized business dedicated

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

VIA M. CIVITALI 1

20148 MILAN, ITALY

TEL. +(39) 024 87 871

FAX +(39) 024 007 3747

€ 26,140,644.50 SHARE CAPITAL, FULLY PAID IN

MILAN, MONZA, BRIANZA and LODI BUSINESS REGISTER 00748210150

TAX CODE/VAT NO. 00748210150

MILAN ECONOMIC AND ADMINISTRATIVE INDEX 401832

Company under the Management and Coordination of Rossini Luxembourg S.à.r.l



*to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

*For further information:*

*Recordati website: [www.recordati.com](http://www.recordati.com)*

**Investor Relations**

*Federica De Medici*

*(39)0248787146*

*e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)*

**Media Relations**

*Studio Noris Morano*

*(39)0276004736, (39)0276004745*

*e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)*

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*